Durata Therapeutics, Inc. 4/A

Accession 0001209191-14-070148

CIK 0001544116operating

Filed

Nov 18, 7:00 PM ET

Accepted

Nov 19, 7:14 PM ET

Size

16.3 KB

Accession

0001209191-14-070148

Form 4/AAmended

Period: 2014-08-26

Director10% Owner

Transactions

Exercise/Conversion
Stock Option (right to buy)
2014-08-26−6,250→ 0 total(indirect: See Footnote)
Exercise: $2.08Exp: 2022-02-27→ Common Stock (6,250 underlying)
Exercise/Conversion
Common Stock
2014-08-26$2.08/sh+5,034$10,471→ 5,034 total(indirect: See Footnote)
Exercise/Conversion
Restricted Stock
2014-08-26−1,216→ 1,216 total(indirect: See Footnote)
Exercise: $0.00→ Common Stock (1,216 underlying)

Holdings

Director10% Owner

Transactions

Exercise/Conversion
Common Stock
2014-08-26$2.08/sh+5,034$10,471→ 5,034 total(indirect: See Footnote)
Exercise/Conversion
Restricted Stock
2014-08-26−1,216→ 1,216 total(indirect: See Footnote)
Exercise: $0.00→ Common Stock (1,216 underlying)
Exercise/Conversion
Stock Option (right to buy)
2014-08-26−6,250→ 0 total(indirect: See Footnote)
Exercise: $2.08Exp: 2022-02-27→ Common Stock (6,250 underlying)

Holdings

Director

Transactions

Exercise/Conversion
Restricted Stock
2014-08-26−1,216→ 1,216 total(indirect: See Footnote)
Exercise: $0.00→ Common Stock (1,216 underlying)
Exercise/Conversion
Stock Option (right to buy)
2014-08-26−6,250→ 0 total(indirect: See Footnote)
Exercise: $2.08Exp: 2022-02-27→ Common Stock (6,250 underlying)
Exercise/Conversion
Common Stock
2014-08-26$2.08/sh+5,034$10,471→ 5,034 total(indirect: See Footnote)

Holdings

Footnotes (4)

[F1]Shares held directly by Mr. Brenton Ahrens, a member and manager of Canaan LLC and a vice-president of Canaan Management, Inc. ("Canaan Management"). Mr. Ahrens, pursuant to an agreement with Canaan Management, is contractually obligated to assign any remuneration received for service as a director to Canaan Management. Each of Canaan VIII L.P ("Canaan L.P.") and its general partner, Canaan Partners VIII LLC ("Canaan LLC") and Canaan Management (collectively, the "Canaan Entities") disclaims beneficial ownership in the securities aheld by Mr. Ahrens, except to the extent, if any, of its pecuniary interest therein.
[F2]Shares held directly by Canaan L.P. Canaan LLC, the general partner of Canaan L.P., may be deemed to share voting, investment and dispositive power with respect to shares held by Canaan L.P., but disclaims beneficial ownership of the securities held by Canaan L.P. except to the extent of any pecuniary interest therein.
[F3]This option was granted on February 28, 2012 to Mr. Ahrens with respect to 6,250 shares of common stock, vesting in 36 substantially equal monthly installments over a three year period, the first installment of which vested on March 28, 2012.
[F4]Shares of common stock which vest in 7 substantially equal monthly installments, the first installment of which vested on August 28, 2014. These shares have no expiration date.

Documents

2 files

Durata Therapeutics, Inc.

CIK 0001544116

Entity typeoperating

IncorporatedDE